| Autor: |
Onishi, Akio, Matsumura-Kimoto, Yayoi, Mizutani, Shinsuke, Isa, Reiko, Fujino, Takahiro, Tsukamoto, Taku, Miyashita, Akihiro, Okumura, Keita, Nishiyama, Daichi, Hirakawa, Koichi, Shimura, Kazuho, Kaneko, Hiroto, Kiyota, Miki, Kawata, Eri, Takahashi, Ryoichi, Kobayashi, Tsutomu, Uchiyama, Hitoji, Uoshima, Nobuhiko, Nukui, Yoko, Shimura, Yuji |
| Zdroj: |
International Journal of Hematology; Jan2024, Vol. 119 Issue 1, p50-61, 12p |
| Abstrakt: |
Multiple myeloma reduces cellular and humoral immunity. Optimal prediction of antibody response to anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with MM and related disorders is essential to prevent coronavirus disease 2019 (COVID-19) during the SARS-CoV-2 pandemic. This study analyzed the humoral response to the anti-SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine and its associated factor in 83 patients from June to November 2021 at seven member institutions of the Kyoto Clinical Hematology Study Group. SARS-CoV-2 neutralizing antibody (nAb) was measured from 12 to 210 days. The result revealed that 40 (48.2%) patients with MM and 59 (100%) healthy controls became seropositive after vaccination. Receiver operating characteristic curve analysis identified serum immunoglobulin (Ig) M of > 18 mg/dL at vaccination as the optimal threshold level associated with seropositivity in the whole cohort. Moreover, the multivariate analysis identified serum IgM of > 18 mg/dL as the independent predictor for a favorable response. Serum IgA level was positively associated with vaccine response in a sub-cohort. Our findings indicate a significant association between immunoparesis and impaired humoral response against mRNA vaccination, including that against SARS-CoV-2, and that serum non-M-protein Ig levels can serve as surrogate biomarkers of nAb production ability. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink